miRagen Therapeutics is a biopharmaceutical company discovering and developing innovative microRNA (miRNA)-targeting therapies to improve human health, specifically in disease areas of high unmet medical need. The Company leverages in-house expertise in miRNA biology, oligonucleotide chemistry, and drug development to evaluate and advance best-in-class technologies and high-potential drug candidates for its own pipeline or in conjunction with strategic partners.
Type
Public
HQ
Boulder, US
Founded
2007
Size (employees)
51 (est)
miRagen Therapeutics was founded in 2007 and is headquartered in Boulder, US
Report incorrect company information

miRagen Therapeutics Office Locations

miRagen Therapeutics has an office in Boulder
Boulder, US (HQ)
6200 Lookout Rd.
Show all (1)
Report incorrect company information

miRagen Therapeutics Financials and Metrics

miRagen Therapeutics Financials

USD

Revenue (Q1, 2018)

4.8 m

Net income (Q1, 2018)

(4.7 m)

EBIT (Q1, 2018)

(4.6 m)

Market capitalization (14-Jun-2018)

219.5 m

Closing share price (14-Jun-2018)

7.3

Cash (31-Mar-2018)

78.1 m

EV

161.4 m
miRagen Therapeutics's current market capitalization is $219.5 m.
USDQ1, 2018

Revenue

4.8 m

General and administrative expense

3 m

R&D expense

6.4 m

Operating expense total

9.4 m
USDQ1, 2018

Cash

78.1 m

Accounts Receivable

4.8 m

Current Assets

86.4 m

PP&E

589 k
USDQ1, 2018

Net Income

(4.7 m)

Depreciation and Amortization

69 k

Accounts Payable

(146 k)

Cash From Operating Activities

(7.4 m)
USDY, 2018

EV/EBIT

-35 x

EV/CFO

-21.9 x

Financial Leverage

1.2 x
Show all financial metrics
Report incorrect company information

miRagen Therapeutics Online and Social Media Presence

Embed Graph
Report incorrect company information